BusinessNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXJun 20, 2017, 1:47 AM UTC
BusinessNeos Therapeutics to Present at 2017 UBS Global Healthcare ConferenceBy Nasdaq OMXMay 16, 2017, 11:31 AM UTC
BusinessNeos Therapeutics to Present at 2017 UBS Global Healthcare ConferenceBy Nasdaq OMXMay 16, 2017, 11:31 AM UTC
BusinessNeos Therapeutics Reports Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 14, 2017, 11:00 AM UTC
BusinessNeos Therapeutics to Host Fourth Quarter and Year-End 2016 Financial Results Conference Call on March 14, 2017By Nasdaq OMXMar 8, 2017, 12:30 PM UTC
BusinessNeos Therapeutics to Present at the Cowen and Company 37th Annual Health Care ConferenceBy Nasdaq OMXFeb 28, 2017, 12:30 PM UTC
BusinessNeos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare ConferenceBy Nasdaq OMXFeb 16, 2017, 12:30 PM UTC
BusinessNeos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHDBy Nasdaq OMXDec 20, 2016, 12:30 PM UTC
